Research Shows Multiple Promising Alzheimer's Treatments

Recent studies highlight promising developments in Alzheimer's treatment focusing on amyloid beta removal and innovative therapies. A study on the anti-amyloid drug gantenerumab indicated that long-term treatment could potentially delay symptoms in genetically predisposed individuals, despite the study being halted early due to regulatory challenges. Additionally, researchers at Washington University reported that gantenerumab could reduce the risk of developing Alzheimer's by 50% among those with genetic mutations, reinforcing the efficacy of anti-amyloid therapies. Meanwhile, a new ultrasound therapy discovered by the Queensland Brain Institute shows potential for non-invasive cognitive restoration without drugs, suggesting a novel approach to treatment. Galimedix Therapeutics is also advancing an oral amyloid beta aggregation modulator, GAL-201, which shows promise in pre-clinical trials for modifying disease progression. These findings collectively underscore a hopeful trajectory for Alzheimer's research, emphasizing both drug-based and non-drug approaches to tackle this debilitating disease.